RIDER Lung PET-CT | RIDER Lung PET-CT

DOI: 10.7937/k9/tcia.2015.ofip7tvm | Data Citation Required | Image Collection

Summary

 The RIDER Lung PET-CT collection was shared to facilitate the RIDER PET/CT subgroup activities. The PET/CT subgroup was responsible for: (1) archiving de-identified DICOM serial PET/CT phantom and lung cancer patient data in a public database to provide a resource for the testing and development of algorithms and imaging tools used for assessing response to therapy, (2) conducting multiple serial imaging studies of a long half-life phantom to assess systemic variance in serial PET/CT scans that is unrelated to response, and (3) identifying and recommending methods for quantifying sources of variance in PET/CT imaging with the goal of defining the change in PET measurements that may be unrelated to response to therapy, thus defining the absolute minimum effect size that should be used in the design of clinical trials using PET measurements as end points.

About the RIDER project

The Reference Image Database to Evaluate Therapy Response (RIDER) is a targeted data collection used to generate an initial consensus on how to harmonize data collection and analysis for quantitative imaging methods applied to measure the response to drug or radiation therapy.  The National Cancer Institute (NCI) has exercised a series of contracts with specific academic sites for collection of repeat "coffee break," longitudinal phantom, and patient data for a range of imaging modalities (currently computed tomography [CT] positron emission tomography [PET] CT, dynamic contrast-enhanced magnetic resonance imaging [DCE MRI], diffusion-weighted [DW] MRI) and organ sites (currently lung, breast, and neuro). The methods for data collection, analysis, and results are described in the new Combined RIDER White Paper Report (Sept 2008):

• RIDER White Paper: Combined contracts report (Sept 2008) PDF

The long term goal is to provide a resource to permit harmonized methods for data collection and analysis across different commercial imaging platforms to support multi-site clinical trials, using imaging as a biomarker for therapy response. Thus, the database should permit an objective comparison of methods for data collection and analysis as a national and international resource as described in the first RIDER white paper report (2006):

• RIDER White Paper: Executive Summary PDF
• RIDER White Paper: Editorial in Nature.com

Data Access

Version 2: Updated 2015/12/29

It was brought to our attention that RIDER-1817358092 and RIDER-2617411955 appeared to be the same patient.  We have gone back to University of Washington and confirmed this is to be true.  RIDER-1817358092 has been removed as RIDER-2617411955 contained a couple additional series that were absent from the patient ID we removed.

Additional Resources for this Dataset

The NCI Cancer Research Data Commons (CRDC) provides access to additional data and a cloud-based data science infrastructure that connects data sets with analytics tools to allow users to share, integrate, analyze, and visualize cancer research data.

• Imaging Data Commons (IDC) (Imaging Data)
• IDC Zenodo community dataset: Image segmentations produced by BAMF under the AIMI Annotations initiative

Citations & Data Usage Policy

Data Citation Required: Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution must include the following citation, including the Digital Object Identifier: